Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1-40/Aβ1-42 in Alzheimer’s disease with PS1 mutations

References

• www.metalife.com/OMIM/104300
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353–6
   PubMed Web of Science ®Google Scholar
• Sherrington R, Rogaev EL, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754–60
   PubMed Web of Science ®Google Scholar
• Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Chi H, et al. Screening for PSEN1 mutations in a referral-based series of AD cases. Neurology 2001;57:621–5
   PubMedGoogle Scholar
• Ikeda M, Sharma V, Sumi SM, Rogaeva EA, Poorkaj P, Sherrington R, Nee L, et al. The clinical phenotypes of two missense mutations in the presenilin 1 gene in Japanese patients. Ann Neurol 1996;40:912–17
   PubMedGoogle Scholar
• Alzheimer Reasearch Forum.Available from: http://www.alzforum.org/
   Google Scholar
• Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991;251:675–8
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T, Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett 1992;148:202–6
   PubMed Web of Science ®Google Scholar
• Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17–26
   PubMed Web of Science ®Google Scholar
• Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555–62
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91–4
   PubMed Web of Science ®Google Scholar
• Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150–6
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481–96
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177–87
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 2011;31:37–44
   PubMedGoogle Scholar
• Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, et al. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. Neurol Neurosurg Psychiatry 2011;82:160–4
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   PubMed Web of Science ®Google Scholar
• Holsinger T, Deveau J, Boustani M, Williams JW. Does this patient have dementia? JAMA 2007;297:2391–404
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stagePCR. Lancet 1991;337:1158–9
   PubMed Web of Science ®Google Scholar
• Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, et al. Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81:608–10
   PubMed Web of Science ®Google Scholar
• Ikeda M, Hirayanagi K, Arai M, Kakuda S, Makioka K, Furuta N, Takai E, et al. Encephalopathy with amyloid angiopathy and numerous amyloid plaques with low levels of CSF Aβ1-40/Aβ1-42. Amyloid 2012;19:186–90
   PubMed Web of Science ®Google Scholar
• Kakuda N, Shoji M, Arai H, Furukawa K, Ikeuchi T, Akazawa K, Takami M, et al. Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med 2012;4:344–52
   PubMedGoogle Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with α synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2019;9:119–28
   Google Scholar
• McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–9
   PubMed Web of Science ®Google Scholar
• Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, Blankenstein MA, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007;69:1006–11
   PubMed Web of Science ®Google Scholar
• Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 2010;5:2
   PubMed Web of Science ®Google Scholar
• Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365–70
   PubMedGoogle Scholar
• Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Ohtake H, Suzuki M, et al. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol 2005;57:429–34
   PubMedGoogle Scholar
• Yoshimoto M, Iwai A, Kang D, Otero D, Xia Y, Saitoh T. NACP, the precursor protein of the non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation. Proc Natl Acad Sci USA 1995;92:9141–5
   PubMedGoogle Scholar